Clinical Trial Update: Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) [Phase 2]

View source ↗

Summary

Daiichi Sankyo reported an update on valemetostat tosylate (DS-3201b), an EZH1/2 dual inhibitor, in a Phase 2 trial (VALENTINE-PTCL01) for relapsed/refractory p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma
• T-cell Leukemia Lymphoma

Drugs mentioned

• Valemetostat Tosylate (valemetostat tosylate)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-07-22